Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
American Gene Technologies International Inc. has 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 3 distinct examiners across 2 distinct art units. GINA PRONZATI is the busiest examiner for the portfolio, currently managing 2 pending office actions. This means a portion of the company's pending actions are consolidated under a single examiner, while the other actions are split between other distinct examiners.
The concentration of 4 pending actions into only 2 distinct art units suggests a focus within the broader biotechnology field. With 3 distinct examiners involved, the company must navigate different individual preferences, though the influence of GINA PRONZATI is significant due to her 2 pending cases. This structure allows for consistency in the 2 art units while still requiring engagement with multiple examiners. The 4 pending office actions represent the current active workload for this portfolio at the USPTO within the Biotechnology & Pharmaceuticals technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (60%) |
| Double-patenting only | 1 (20%) |
| Double-patenting + other | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRONZATI, GINA | 2 | 66.7% | +45.9% |
| SALVOZA, M FRANCO G | 1 | 68.4% | +30.0% |
| KINSEY WHITE, NICOLE ERIN | 1 | 58.1% | +16.4% |
| PARKIN, JEFFREY S | 1 | 63.7% | +21.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18227775 | ON DEMAND EXPRESSION OF EXOGENOUS FACTORS IN LYMPHOCYTES | PRONZATI, GINA | 81d overdue |
| 18615749 | PRE-IMMUNIZATION AND IMMUNOTHERAPY | SALVOZA, M FRANCO G | — |
| 18540621 | HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY | KINSEY WHITE, NICOLE ERIN | — |
| 17908509 | ON DEMAND EXPRESSION OF EXOGENOUS FACTORS IN LYMPHOCYTES TO TREAT HIV | PRONZATI, GINA | — |
| 16652867 | VECTORS WITH PROMOTER AND ENHANCER COMBINATIONS FOR TREATING PHENYLKETONURIA | PARKIN, JEFFREY S | — |
| Art Unit | Apps |
|---|---|
| 1672 | 2 |
| 1633 | 2 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18615749 | PRE-IMMUNIZATION AND IMMUNOTHERAPY | SALVOZA, M FRANCO G | 1672 | §103§112DP | Non-Final OA | — | Pending | Mar 25, 2024 |
| 18540621 | HIV PRE-IMMUNIZATION AND IMMUNOTHERAPY | KINSEY WHITE, NICOLE ERIN | 1672 | DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18227775 | ON DEMAND EXPRESSION OF EXOGENOUS FACTORS IN LYMPHOCYTES | PRONZATI, GINA | 1633 | §112 | Final Rejection | 81d overdue | Pending | Jul 28, 2023 |
| 17908509 | ON DEMAND EXPRESSION OF EXOGENOUS FACTORS IN LYMPHOCYTES TO TREAT HIV | PRONZATI, GINA | 1633 | §112 | Final Rejection | — | Pending | Aug 31, 2022 |
| 16652867 | VECTORS WITH PROMOTER AND ENHANCER COMBINATIONS FOR TREATING PHENYLKETONURIA | PARKIN, JEFFREY S | 1671 | §112 | Non-Final OA | — | Pending | Apr 01, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial